Abstract

BackgroundLesinurad (LESUR) is an oral investigational URAT1 inhibitor for the treatment of gout. A Phase 2B study in 208 gout patients with an inadequate response to allopurinol (ALLO) (200-600 mg/day...

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
AB1064 No clinically meaningful drug interactions expected between lesinurad, a novel oral uricosuric agent, and drugs most commonly used by gout patients
...
Annals of the Rheumatic Diseases | VOL. 71
, et. al. ...
01 Jun 2013
FRI0333 Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination with Allopurinol: Results from a Phase III Study in Gout Patients Having an Inadequate Response to Standard of Care (Clear 2)
T Bardin ... C Storgard
Annals of the Rheumatic Diseases | VOL. 74
T Bardin, et. al.T Bardin ... C Storgard
01 Jun 2015
FRI0320 Lesinurad, A Selective URIC Acid Reabsorption Inhibitor, in Combination with Allopurinol: Results from a Phase III Study in Gout Patients Having an Inadequate Response to Standard of Care (Clear 1)
K Saag ... J Kopicko
Annals of the Rheumatic Diseases | VOL. 74
K Saag, et. al.K Saag ... J Kopicko
01 Jun 2015
The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5.
Xuemei Liu ... Tingting Zhai
Clinical and Experimental Nephrology | VOL. 23
Xuemei Liu, et. al.Xuemei Liu ... Tingting Zhai
05 Oct 2018
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
Assessing the performance of AI chatbots in answering patients’ common questions about low back pain
Simone P S Scaff ... Bruno T Saragiotto
Annals of the Rheumatic Diseases | VOL. -
Simone P S Scaff, et. al.Simone P S Scaff ... Bruno T Saragiotto
18 Sep 2024
Human hypofunctional NCF1 variants promote pulmonary fibrosis in the bleomycin-induced mouse model and patients with systemic sclerosis via expansion of SPP1+ monocytes-derived macrophages
Xinran Yuan ... Betty P Tsao
Annals of the Rheumatic Diseases | VOL. -
Xinran Yuan, et. al.Xinran Yuan ... Betty P Tsao
18 Sep 2024
Lupus and inflammatory bowel disease share a common set of microbiome features distinct from other autoimmune disorders
Hao Zhou ... Ilana Brito
Annals of the Rheumatic Diseases | VOL. -
Hao Zhou, et. al.Hao Zhou ... Ilana Brito
18 Sep 2024
Is a 1-year course of methotrexate in patients with arthralgia at-risk for rheumatoid arthritis cost-effective? A cost-effectiveness analysis of the randomised, placebo-controlled TREAT EARLIER trial
Elise Van Mulligen ... Annette Van Der Helm-Van Mil
Annals of the Rheumatic Diseases | VOL. -
Elise Van Mulligen, et. al.Elise Van Mulligen ... Annette Van Der Helm-Van Mil
18 Sep 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.